Myriad Genetics Inc (NAS:MYGN)
$ 25.29 0.7 (2.84%) Market Cap: 2.29 Bil Enterprise Value: 2.33 Bil PE Ratio: 0 PB Ratio: 3.01 GF Score: 76/100

Myriad Genetics Inc at JPMorgan Healthcare Conference Transcript

Jan 11, 2024 / 12:30AM GMT
Release Date Price: $19.75 (+8.28%)
Rachel Marie Vatnsdal Olson
JPMorgan Chase & Co, Research Division - Analyst

Perfect. Hello, everyone. Good afternoon. This is Rachel Vatnsdal Olson with the life science tools and diagnostics team here at JPMorgan. I'm joined by Paul Diaz, CEO of Myriad here. And so this will be a 40-minute session, roughly 20, 25 minutes of our presentation followed by Q&A.

And so with that, I'll pass it over to you.

Paul J. Diaz
Myriad Genetics, Inc. - CEO, President & Director

Thanks, Rachel. Great to be here, and thank you all for attending late in the day. I'm sure it's been a long day for everyone. Really excited to present and give you an update on the progress that we're making at Myriad Genetics. It's been a busy but good year for us. And so we'll dive in. And again, we'll have some time for questions as I doubt I will take more than 25 minutes. So thanks again for your participation.

For those of you participating online, we encourage you to look at the presentation. And at the end, we will give some reconciliations in terms of our

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot